A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
Checked against the public recordLast updated Aug 22, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Merrimack Pharmaceuticals
- Interventions being studied
- Drug: MM-121; Drug: Erlotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients with locally advanced or metastatic non-small cell lung cancer. * Patients must be \>/= 18 years of age. * Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function. Exclusion Criteria: * Patients with a recent history (within 5 years) of another malignancy. * Patients who are pregnant or nursing. * Patients with clinically significant heart failure. * Patients with clinically significant eye or gastrointestinal abnormalities.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Study locationBirmingham, Alabama
- Study locationTucson, Arizona
- Study locationLoma Linda, California
- Study locationSacramento, California
- Study locationSan Francisco, California
- Study locationAurora, Colorado
- Study locationTampa, Florida
- Study locationAtlanta, Georgia
- Study locationLafayette, Indiana
- Study locationBoston, Massachusetts
- Study locationSt Louis, Missouri
- Study locationBuffalo, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 22, 2016. Always confirm current availability with the study team.